These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3277185)

  • 1. Chimeric proteins define variable and essential regions of Ha-ras-encoded protein.
    Lowe DG; Ricketts M; Levinson AD; Goeddel DV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1015-9. PubMed ID: 3277185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterologous expression and characterization of the human R-ras gene product.
    Lowe DG; Goeddel DV
    Mol Cell Biol; 1987 Aug; 7(8):2845-56. PubMed ID: 3313005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of p21 ras proteins.
    Shih TY; Hattori S; Clanton DJ; Ulsh LS; Chen ZQ; Lautenberger JA; Papas TS
    Gene Amplif Anal; 1986; 4():53-72. PubMed ID: 3333361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
    Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
    Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophosphorylation of v-Ha-ras p21 is modulated by amino acid residue 12.
    Gibbs JB; Ellis RW; Scolnick EM
    Proc Natl Acad Sci U S A; 1984 May; 81(9):2674-8. PubMed ID: 6609366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural differences between a ras oncogene protein and the normal protein.
    Tong LA; de Vos AM; Milburn MV; Jancarik J; Noguchi S; Nishimura S; Miura K; Ohtsuka E; Kim SH
    Nature; 1989 Jan; 337(6202):90-3. PubMed ID: 2642607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of functional domains of p21 ras by use of chimeric genes.
    Schejter ED; Shilo BZ
    EMBO J; 1985 Feb; 4(2):407-12. PubMed ID: 3926484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes.
    Bradley MO; Kraynak AR; Storer RD; Gibbs JB
    Proc Natl Acad Sci U S A; 1986 Jul; 83(14):5277-81. PubMed ID: 3523488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of NIH3T3 cells with synthetic c-Ha-ras genes.
    Kamiya H; Miura K; Ohtomo N; Koda T; Kakinuma M; Nishimura S; Ohtsuka E
    Jpn J Cancer Res; 1989 Mar; 80(3):200-3. PubMed ID: 2542206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of amino acid residues required for Ras p21 target activation.
    Marshall MS; Davis LJ; Keys RD; Mosser SD; Hill WS; Scolnick EM; Gibbs JB
    Mol Cell Biol; 1991 Aug; 11(8):3997-4004. PubMed ID: 1906576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementation by BCL2 and C-HA-RAS oncogenes in malignant transformation of rat embryo fibroblasts.
    Reed JC; Haldar S; Croce CM; Cuddy MP
    Mol Cell Biol; 1990 Aug; 10(8):4370-4. PubMed ID: 2196451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.
    Geiser AG; Der CJ; Marshall CJ; Stanbridge EJ
    Proc Natl Acad Sci U S A; 1986 Jul; 83(14):5209-13. PubMed ID: 3523486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 associates with the ras-related protein R-ras p23.
    Fernandez-Sarabia MJ; Bischoff JR
    Nature; 1993 Nov; 366(6452):274-5. PubMed ID: 8232588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.
    La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP
    Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of myeloid cell growth by distinct effectors of Ras.
    Matsuguchi T; Kraft AS
    Oncogene; 1998 Nov; 17(21):2701-9. PubMed ID: 9840934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production and characterization of monoclonal antibodies to Ha-ras and N-ras p21.
    Ng S; Conlon J; Lavecchio J; Hamer PJ; Pullano T; Carney WP
    Hybridoma; 1991 Aug; 10(4):467-80. PubMed ID: 1937497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and biological activities of N-ras proteins.
    Geis AM; Nicolson M; Goldman RA
    Biochem Biophys Res Commun; 1986 Sep; 139(2):771-9. PubMed ID: 3533068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated conformations of the ras-gene-encoded p21 protein. 1. An energy-refined structure for the normal p21 protein complexed with GDP.
    Dykes DC; Brandt-Rauf P; Luster SM; Chung D; Friedman FK; Pincus MR
    J Biomol Struct Dyn; 1992 Jun; 9(6):1025-44. PubMed ID: 1637501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells.
    Daaka Y; Wickstrom E
    Oncogene Res; 1990; 5(4):267-75. PubMed ID: 2204019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant but not normal p21 ras elevates inositol phospholipid breakdown in two different cell systems.
    Hancock JF; Marshall CJ; McKay IA; Gardner S; Houslay MD; Hall A; Wakelam MJ
    Oncogene; 1988 Aug; 3(2):187-93. PubMed ID: 2842715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.